How AI Is Moving From Promise to Practice in Pharmacovigilance

April 7, 2026 - 05:43

The field of pharmacovigilance, dedicated to monitoring drug safety, is witnessing a tangible shift as artificial intelligence moves beyond theoretical promise into practical, operational use. This transition, however, is progressing at an uneven pace across the global pharmaceutical industry.

In a recent discussion, industry expert Gary Barker detailed the evolving landscape. He highlighted that AI's primary impact is currently felt in automating and enhancing the initial processing of vast volumes of safety data. Advanced algorithms are now routinely employed to triage adverse event reports, identify potential duplicates, and perform initial data entry with increasing accuracy, freeing human experts for more complex analysis.

Despite this progress, significant challenges to widespread adoption persist. Barker pointed to data quality and standardization as major hurdles, noting that AI models are only as reliable as the data they are trained on. Furthermore, navigating stringent regulatory expectations for transparent and validated AI processes remains a critical focus for companies.

Emerging best practices are now centered on a collaborative model. The most successful implementations, Barker explained, involve tight integration between AI systems and pharmacovigilance professionals. This human-in-the-loop approach ensures that AI handles high-volume, repetitive tasks while experts provide crucial oversight, contextual understanding, and make final medical assessments. This synergy is proving essential for building trust in AI-driven insights and ensuring robust patient safety surveillance in the era of big data.